The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy by unknown
1 3
Cancer Chemother Pharmacol (2016) 77:653–657
DOI 10.1007/s00280-015-2940-3
SHORT COMMUNICATION
The pharmacokinetics of high‑dose methotrexate in people living 
with HIV on antiretroviral therapy
Alessia Dalla Pria1 · Maggie Bendle1 · Ramya Ramaswami1 · Marta Boffito2 · 
Mark Bower1 
Received: 3 November 2015 / Accepted: 7 December 2015 / Published online: 22 December 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
NRTI backbones did not affect MTX elimination kinetics 
(p = 0.68), despite the potential overlapping competition 
for active renal tubular transporters between MTX and 
tenofovir.
Conclusion Although there is potential competition for 
active renal tubular transporters between MTX and tenofo-
vir, no prolongation of MTX half-life was observed. These 
findings are reassuring to clinicians managing patients with 
dual diagnoses.
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Introduction
Human immunodeficiency virus (HIV) infection substan-
tially increases the risk of developing non-Hodgkin lym-
phoma (NHL) [1]. This is attributable to impaired cel-
lular immunity and increased susceptibility to oncogenic 
viruses. The two most frequent histological subtypes of 
NHL subtypes in people living with HIV (PLWH) are dif-
fuse large B cell lymphoma (DLBCL) and Burkitt lym-
phoma (BL) which are AIDS-defining illnesses. Burkitt/
Burkitt-like lymphoma (BL/BLL) accounts for 25–40 % of 
HIV-associated NHL [2]. In the HIV-negative population, 
BL is a highly curable cancer if treated with intensive, short 
duration, chemotherapy regimens. High intravenous doses 
of the anti-metabolite methotrexate (MTX), with folinic 
acid rescue, are an integral part of the treatment.
(R)-CODOX-M/IVAC (rituximab, cyclophosphamide, 
vincristine, doxorubicin, methotrexate/ifosfamide, etopo-
side, cytarabine) is the standard chemotherapy regimen 
for BL/BLL in the UK and includes 3 g/m2 methotrexate. 
This regimen is used with antiretroviral therapy in PLWH 
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MTX concentration was measured (ARK TM MTX assay, 
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diagnosed with BL/BLL and has been shown to achieve 
outcomes comparable to the HIV-negative patients (com-
plete remission rate of 84 % and a 2-year overall survival 
of 73 %) [3–6].
However, chemotherapy in PLWH may be complicated 
by clinically significant pharmacokinetic interactions 
between cytotoxic drugs and antiretrovirals (ARVs). No 
data on the pharmacokinetics (PK) of high-dose MTX in 
PLWH are available. We investigated MTX PK and evalu-
ated the effects of renal function (eGFR), age and use of 
different classes of ARVs.
Methods
All people living with HIV (PLWH) treated with (R)-
CODOX-M/IVAC for HIV-associated Burkitt/Burkitt-like 
lymphoma between 2007 and 2014 at the National Cen-
tre for HIV Malignancy, Chelsea and Westminster Hospi-
tal, London, are included in the analysis. As part of rou-
tine care, following methotrexate infusion (3 g/m2) plasma 
was collected and sent to Great Ormond Street Hospital 
for Children in London for MTX concentration measure-
ment (ARK TM MTX assay, VITROS 5600) daily. Treat-
ment with folinic acid rescue and urinary alkalinization 
continued until MTX concentrations <0.05 mmol/L were 
achieved. No patients received glucarpidase as salvage for 
methotrexate toxicity. Clinical data on renal, liver function 
and ARV regimen (nucleoside reverse transcriptase inhibi-
tors (NRTIs) backbones and use of third agent) were col-
lected. Comparison of MTX elimination half-life (t½) with 
relevant clinical variables was performed using t test (Stat-
View 1989).
Results
We treated 43 PLWH (8 women, 35 men) with HIV-asso-
ciated BL/BLL with (R)-CODOX-M/IVAC. At the start of 
chemotherapy, the mean age was 42 years (range 24–71) 
and the mean duration of HIV infection was 28 months 
(range 0–295). Two (5 %) had a prior AIDS-defining ill-
ness, and 12 (28 %) were established on combination 
antiretroviral therapy (cART) prior to lymphoma diagnosis, 
of whom ten (83 %) had an undetectable plasma HIV viral 
load. For the whole cohort, the median CD4 cell count was 
225 cells/mm3 (range 10–864), the median CD4 percentage 
13 % (range 2–39), the median CD8 cell count 884 cells/
mm3 (range 272–2065) and the median CD8 percentage 
55 % (range 22–77). The median plasma HIV viral load for 
the cohort was 10,860 copies/mL (range 0–1.9 M).
The combination antiretroviral therapy that was con-
comitantly prescribed with the methotrexate included 36 
(84 %) patients on a nucleotide/side reverse transcriptase 
inhibitor (NRTI) backbone of tenofovir/emtricitabine back-
bone and seven (16 %) on a backbone of abacavir/lamivu-
dine. Twenty-two (51 %) patients were on integrase inhibi-
tors (INI), 18 (42 %) on non-NRTIs (NNRTIs), one (2 %) 
on a ritonavir-boosted protease inhibitor, one (2 %) on both 
NNRTI and INI, and one (2 %) on INI and maraviroc.
A total of 183 methotrexate levels were assayed follow-
ing administration of 3 g/m2 methotrexate, but accurate 
timings of the sample collection were not available for 
33 samples. The 150 timed MTX levels from 43 PLWH 
included 18 samples from women and 132 from men. The 
median half-life (t½) of methotrexate was 21.7 h (range 
9.4–204.4). The elimination half-life of methotrexate was 
not affected by eGFR (p = 0.67) (Fig. 1c) or age (p = 0.71) 
(Fig. 1d). There was no difference in methotrexate elimi-
nation kinetics between patients on non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and those on integrase 
inhibitors (p = 0.15) (Fig. 1a). There was no difference in 
methotrexate elimination kinetics between patients on dif-
ferent NRTI backbones (p = 0.68) (Fig. 1b).
Elevated serum concentrations of methotrexate at 24, 48 
and 72 h (in excess of 20, 2 and 0.2 µM, respectively) were 
recorded for 31/150 (21 %) time points. An elevated level 
was not associated with use of NNRTIs rather than inte-
grase inhibitors (p = 0.8) or by NRTI backbones (p = 0.9). 
Following methotrexate, only one patient developed 
CTCv4.0 grade 1 acute nephrotoxicity, and his elimination 
half-life of methotrexate was 38.8 h.
Discussion
Pharmacokinetic drug interactions can significantly affect 
the efficacy and toxicity of chemotherapy. The most fre-
quent mechanism of these interactions is the inhibition and 
induction of hepatic cytochrome P450 (CYP) microsomal 
enzymes by co-administered drugs. The CYP enzymes are 
responsible for the vast majority of drug metabolic deac-
tivation and clearance. Many drugs including antiretrovi-
ral agents increase or decrease the activity of various CYP 
isoenzymes by inducing their biosynthesis or by inhibiting 
their activity, resulting in adverse drug interactions. For 
example, ritonavir is a potent inhibitor of CYP3A4 activ-
ity, leading to increased bioavailability of many of the 
substrates of CYP3A4 including cytotoxic chemotherapy 
agents, and resulting in overdosing and excess toxicity. 
This pharmacological drug interaction has been shown to 
be of clinical significance in treating patients with HIV-
associated lymphoma. Patients receiving ritonavir-boosted 
PI-based cART experienced greater myelosuppression 
and subsequently increased the risk of hospitalization for 
severe neutropenic sepsis with CDE (cyclophosphamide, 
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doxorubicin and etoposide) for HIV-associated NHL [7]. 
Since cyclophosphamide, vincristine, doxorubicin, ifos-
famide and etoposide, all components of CODOX-M/
IVAC chemotherapy, are substrates of CYP3A4, ritonavir-
boosted PIs are avoided and all but one of our patients were 
prescribed NNRTI-based and integrase inhibitor-based 
ARV regimens. Furthermore, ritonavir has been shown to 
inhibit the activity of organic anion transporters (OATs) and 
organic cation transporters (OCTs), which are expressed in 
numerous organs, including the kidneys and the liver, and 
Fig. 1  Half-life elimination of MTX (n = 29 cycles). a Integrase-
based versus NNRTI-based ARV group (p = 0.15). b TDF/FTX 
versus ABC/3TC ARV backbone (p = 0.68). c Elimination of MTX 
was not affected by eGFR (p = 0.67). d Elimination of MTX was not 
affected by age (p = 0.75)
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hence may be responsible for additional drug interactions 
at the cellular level [8].
Methotrexate is eliminated by renal clearance with 
almost 90 % excreted unchanged in the urine. Although 
the mechanism of MTX excretion in the human kidney 
has not been completely elucidated, the finding that MTX 
clearance exceeds creatinine clearance in several studies 
suggests that there is active tubular secretion as well as 
glomerular filtration [9]. The tubular secretion of metho-
trexate is mediated by an organic anion transport system, 
and recent molecular studies have identified multiple can-
didates for organic anion transporters that can mediate 
methotrexate transport in the kidney, including basolateral 
OAT1 and OAT2, multidrug resistance-associated protein 
1(MRP1) and MRP2, and the kidney-specific organic anion 
transporters OATK1 and OATK2. Efficient OAT-mediated 
basolateral uptake could result in high intracellular drug 
concentrations, whereas at the apical-side MRPs control 
the intracellular concentration by active drug efflux into 
urine [10]. The pharmacokinetics of MTX is thus prone to 
drug–drug interactions that occur at the renal transporter 
level. Many drugs inhibit renal excretion of MTX and may 
potentially increase treatment-related toxicity, for exam-
ple NSAIDs, phenytoin, ciprofloxacin, penicillin drugs, 
probenecid, amiodarone and proton pump inhibitors [11]. 
Because urinary excretion is the main route of elimina-
tion, MTX can reach high concentration in the renal tubules 
causing nephrotoxicity [12, 13].
There is a clear relationship between plasma MTX lev-
els, adverse events and treatment efficacy with important 
individual differences [14]. This individual variability can 
be linked to germline polymorphisms of genes involved in 
drug absorption, metabolism, excretion, cellular transport, 
and/or effector targets and pathways [15]. Nevertheless, 
the incidence of toxicity can be substantially reduced by a 
combination of urine alkalinization and optimal hydration 
to encourage renal clearance, folinic acid rescue to negate 
the effects of MTX on normal cells and plasma MTX drug 
monitoring to determine when it is safe to cease these 
measures [12]. All this procedures are carefully applied 
in the CODOX-M/IVAC protocol for our HIV-positive 
patients with BL/BLL lymphoma at Chelsea and Westmin-
ster Hospital.
In this study, we evaluated the clearance of MTX in 
PLWH receiving 3 g/m2 MTX as part of the CODOX-M/
IVAC regimen with concomitant cART. While the defini-
tion of high-dose MTX is not clear in the literature, the 
overall plasma half-life (t½) of MTX following intrave-
nous administered as a dose >30 mg/m2 is 8–12 h, although 
this may be longer when higher doses such as 3 g/m2 are 
administered [11].
The median plasma MTX half-life in our study popula-
tion was 21.7 h (range 9.4–204.4). There was no significant 
difference in MTX clearance in patients with reduced eGFR 
(p = 0.67); this is surprising since impaired renal func-
tion reduces MTX elimination, but only 29 (19 %) sam-
ples were taken from patients with estimated GFR below 
90 mL/min. Similarly, age did not influence plasma MTX 
half-life (p = 0.71). This has been previously demonstrated 
in the HIV-negative setting where no significant reduction 
in MTX clearance was observed in older (>60 years old) 
patients treated with 4 g/m2 for primary central nervous 
system lymphoma [16].
The influence of co-administered ARVs on MTX elimi-
nation was evaluated by class of antiretroviral. There was 
no statistically significant difference in half-life between 
patients on non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) and those on integrase inhibitors (p = 0.15). Ten-
ofovir disoproxil fumarate (TDF) is recommended as first-
line nucleotide reverse transcriptase inhibitor (NRTI) for 
HIV-1 treatment. Prolonged treatment with TDF has been 
linked to nephrotoxicity characterized by eGFR decline and 
proximal tubular dysfunction, especially if used in com-
bination with boosted PIs [17]. TDF is a pro-drug that is 
converted to tenofovir and subsequently cleared by renal 
glomerular filtration and active proximal tubular excretion. 
The nephrotoxicity is related to intracellular accumulation 
of tenofovir in proximal tubule cells that results in mito-
chondrial DNA depletion and cytotoxicity. Tenofovir renal 
proximal tubular toxicity is regulated by OAT1 (drug influx 
at basolateral side of tubular cells) and MRP4 (drug efflux 
in the pre-urine) transporters [18]. Thus, there is a clear 
potential for competition for active renal basolateral organic 
anion transporter 1 when tenofovir and methotrexate are co-
administered, which could lead to decreased clearance and 
increased exposure to either drug and therefore to a drug 
interaction at this level even in the absence of ritonavir-
boosted protease inhibitors. Reassuringly, in our cohort of 
patients, there was no difference in MTX half-life between 
patients receiving a TDF-based backbone compared to those 
on TDF-sparing backbones (p = 0.68).
This study has some limitations. Firstly, data have been 
retrospectively collected, and MTX concentration testing 
sent in a real-life clinical practice and not in a pre-sched-
uled clinical trial setting. Important genetic polymorphisms 
influence MTX metabolism, causing pharmacokinetic vari-
ability, but no pharmacogenetic analysis was undertaken in 
this cohort. Finally, the influence of other medications such 
as NSAIDs, penicillin drugs and proton pump inhibitors 
has not been evaluated.
Conclusion
Pharmacological drug–drug interactions in the manage-
ment of HIV-associated lymphomas have had important 
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clinically significant effects. Plasma methotrexate levels 
influence both its efficacy and its toxicity, and the elimina-
tion is by renal clearance. In an analysis of 43 people liv-
ing with HIV who were treated with 3 g/m2 MTX as part 
of chemotherapy for BL/BLL, the elimination half-life of 
MTX was not affected by eGFR, age or ARV regimen. 
This is despite the potential overlapping competition for 
active renal tubular transporters between MTX and teno-
fovir. These findings are reassuring to clinicians managing 
patients with dual diagnoses, but prospective data on the 
PK and the pharmacodynamics of ARV and cytotoxics are 
warranted to improve treatment of cancer in PLWH.
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